Statement Of Cash Flows [Abstract]

Transgene - Filing #2813436

Concept 2022-01-01 to
2022-12-31
2021-01-01 to
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income (cost)
2 900 EUR
3 989 EUR
Cash flows from (used in) operations before changes in working capital
25 393 EUR
19 145 EUR
Adjustments for increase (decrease) in deferred income including contract liabilities [abstract]
Adjustments for increase (decrease) in deferred income including contract liabilities
804,000 EUR
1 124 EUR
Cash flows from (used in) financing activities [abstract]
Payments for share issue costs
- EUR
787,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.